Aardvark Therapeutics Inc

AARD remains in a Stage 2 advance with confirmed higher highs and higher lows, supporting a medium-term bullish bias. Price trades above rising 9/21 EMAs and the 50 DMA but has pulled back into the EMAs after an overextended move, and the Options Score is overbought, indicating that immediate entries are premature. We will stalk pullbacks into the rising EMA zone or near the 50 DMA. A decisive break below the rising EMAs or the 50 DMA with sustained selling would invalidate the bullish thesis.

• ↑ARD-101 Phase II trial targets metabolic disorders with high market potential.
• ↑Dividend yield of 0.74% offers income amid uncertain capital gains.
• ↓Earnings yield of –3.41 indicates significant unprofitability versus price.